Şeyda Atadan Memiş

Şeyda was appointed the General Manager of Takeda in the UK & Ireland in July 2022.

Şeyda has over 20 years of pharmaceutical experience gained across a range of commercial roles. Previously, Şeyda was the GM of Takeda Turkey for four years, and she hopes to utilise her track record of success alongside her external roles to enhance the JPG’s collective impact and positively shape the environment.

In Turkey, Şeyda was a Board member of the Association of Research-Based Pharmaceutical Companies (an affiliate of EFPIA) and the sponsor for Health Economics Policies, where she actively contributed to shaping the pricing scheme with external stakeholders and officials. Şeyda hopes to use her experience in challenging a detrimental commercial environment, which included high inflation and pressure on the medicines budget, to support current UK pricing discussions.

Takeda is over 240 years old, with a presence in approximately 80 countries and expertise across rare disease, oncology, gastroenterology and neuroscience. Takeda is the largest Japanese biopharmaceutical company, and a top 10 company, globally and in the UK. Our UK head office is in Paddington, and we have continued to enhance our presence in the UK by recently becoming a member of the Paddington Life Sciences Partnership, aimed at improving health and supporting innovation. In terms of R&D, the UK and Ireland now accounts for 10% of Takeda’s partnerships globally.

Takeda has been a long-standing member of the JPG, with senior-level representation across key workstreams and our former General Manager elected as Chair of the group for a number of years, all supported by an External Affairs team of Public Affairs and Comms Leads. As the JPG’s Deputy Chair, Şeyda would be committed to championing the potential of Japanese pharmaceutical investment and R&D within the UK and to ensuring our close ties with the ABPI and other industry groups.